Multimorbidity impacts cardiovascular disease risk following percutaneous coronary intervention: latent class analysis of the Melbourne Interventional Group (MIG) registry.

Authors:
Ho CLB; Si S; Brennan A; Briffa T; Stub D and 2 more

Journal:
BMC Cardiovasc Disord

Publication Year: 2024

DOI:
10.1186/s12872-023-03636-7

PMCID:
PMC10804750

PMID:
38262972

Journal Information

Full Title: BMC Cardiovasc Disord

Abbreviation: BMC Cardiovasc Disord

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Vascular Diseases

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Ethics approval and consent to participateThe study was approved by the Curtin University human research ethics committee (HRE2016-0372). Informed consent was waived by the Monash University human research ethics committee. Consent for publicationNot applicable. Competing interestsNo conflict of interest Competing interests No conflict of interest"

Evidence found in paper:

"Funding The Melbourne Interventional Group acknowledges funding from Abbott Vascular, Astra-Zeneca, BMS and Pfizer. These companies do not have access to data and do not have the right to review manuscripts or abstracts before publication. DS research supported by NHF and NHMRC grants. Professor Reid’s work is supported by NHMRC grants (GTN: 1136372)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025